Get in touch with us

Contact Avvio Medical using this form.

1 + 14 =


2325 3rd Street, Suite 215
San Francisco, CA, 94107



SAN FRANCISCO–Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today confirmed that it had successfully raised an additional $7.1M in financing, led by Gudu Medical, for the company’s Series B round. With this investment, the company has completed its entire Series B financing, having raised $34M in funds.

“With the current Series B funding round and investment in our innovative technology we are well positioned financially to complete our ongoing IDE study and begin preparations for the commercial launch of our Acoustic Enhancer technology,” stated Thomas Kenny, PhD, Co-Founder and Chairman of Applaud Medical. “We appreciate the confidence our investors have in our technology and the capability of our team to achieve our planned strategic milestones.”

Applaud Medical’s Acoustic Enhancer technology is designed to be used in conjunction with Ureteroscopy with Laser Lithotripsy (URS-LL) for the fragmentation of calcium-based urinary stones of at least 6mm and not more than 20mm in diameter that are obstructing or deemed to present a significant risk of future obstruction by a urologist or other qualified physician, which can place patients at risk of future sepsis, chronic kidney disease, or end-stage renal disease. The Acoustic Enhancer microparticles generate additional stone-fragmenting shockwaves when used during a laser lithotripsy procedure.

About Applaud Medical, Inc.

Applaud is a privately held company founded in 2014 which aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of kidney stones. The Company is developing the Applaud Acoustic Enhancer, an innovative technology designed to enhance URS-LL in the fragmentation of kidney stones. The Company is also actively conducting a prospective, multicenter, randomized, double-blind study (NCT04563039) for the Acoustic Enhancer when used in conjunction with URS-LL.